Novartis’ Coartem: Will An Unusual Drug Have A Bland Advisory Committee Review?
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis’ malaria combination drug could become the first to generate a priority review voucher under FDA’s new incentive program.